Literature DB >> 21274700

CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Anita J Bechtholt-Gompf1, Karen L Smith, Catherine S John, Hannah H Kang, William A Carlezon, Bruce M Cohen, Dost Ongür.   

Abstract

RATIONALE: In patients, ketamine is a fast-acting antidepressant that can induce long-lasting symptom relief. Similar rapid effects have been reported in rodents, but reports of lasting effects are limited.
OBJECTIVES: We sought to extend past findings by examining dose-response curves that overlap with the individual doses previously reported to induce lasting effects in rodents and determining whether effects generalize to the tail suspension test (TST) and Balb/cJ mice.
METHODS: Using common tests of antidepressant efficacy we first confirmed our ability to detect the effects of desipramine, a well-characterized antidepressant drug. Next, we sought to determine whether two non-competitive NMDA antagonists, ketamine and MK-801, had long-lasting antidepressant-like effects in CD-1 mice, a strain that has often been used to demonstrate the short-term antidepressant-like effects of ketamine. Finally, we examined the short- and long-term effects of ketamine in a mouse strain that is more sensitive to antidepressant-like effects, Balb/cJ mice.
RESULTS: In CD-1 mice, desipramine treatment yielded significant short-term antidepressant-like effects in the TST and the forced swimming test (FST). However, no significant enduring effects of ketamine or MK-801 were observed 1 week later. Short-term effects of ketamine in the TST were observed in Balb/cJ mice, but lasting effects were absent 1 week later.
CONCLUSIONS: Although the TST and FST have been widely used to detect antidepressant-like effects in mice, they do not appear to be sensitive to long-lasting antidepressant-like effects of ketamine in mice and, therefore, do not model the therapeutic effects of ketamine that have been reported in humans with major depression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21274700     DOI: 10.1007/s00213-011-2169-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice.

Authors:  Angelo Oscar Rosa; Jaime Lin; João Batista Calixto; Adair Roberto S Santos; Ana Lúcia S Rodrigues
Journal:  Behav Brain Res       Date:  2003-09-15       Impact factor: 3.332

2.  Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series.

Authors:  G Paslakis; M Gilles; A Meyer-Lindenberg; M Deuschle
Journal:  Pharmacopsychiatry       Date:  2009-12-11       Impact factor: 5.788

3.  Ketamine produces lasting disruptions in encoding of sensory stimuli.

Authors:  Christina R Maxwell; Richard S Ehrlichman; Yuling Liang; Danielle Trief; Stephen J Kanes; Jonathan Karp; Steven J Siegel
Journal:  J Pharmacol Exp Ther       Date:  2005-09-28       Impact factor: 4.030

4.  Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test.

Authors:  James J Crowley; Julie A Blendy; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

5.  Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus.

Authors:  Lêda S B Garcia; Clarissa M Comim; Samira S Valvassori; Gislaine Z Réus; Luciana M Barbosa; Ana Cristina Andreazza; Laura Stertz; Gabriel R Fries; Elaine Cristina Gavioli; Flavio Kapczinski; João Quevedo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-08       Impact factor: 5.067

6.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

7.  Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.

Authors:  E Engin; D Treit; C T Dickson
Journal:  Neuroscience       Date:  2009-03-24       Impact factor: 3.590

8.  Small-dose ketamine improves the postoperative state of depressed patients.

Authors:  Akira Kudoh; Yoko Takahira; Hiroshi Katagai; Tomoko Takazawa
Journal:  Anesth Analg       Date:  2002-07       Impact factor: 5.108

9.  Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test.

Authors:  James J Crowley; Edward S Brodkin; Julie A Blendy; Wade H Berrettini; Irwin Lucki
Journal:  Neuropsychopharmacology       Date:  2006-03-22       Impact factor: 7.853

10.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

View more
  19 in total

1.  Depressive behavior in the forced swim test can be induced by TRPV1 receptor activity and is dependent on NMDA receptors.

Authors:  Ramy E Abdelhamid; Katalin J Kovács; Myra G Nunez; Alice A Larson
Journal:  Pharmacol Res       Date:  2013-11-04       Impact factor: 7.658

2.  Concerns about the antidepressant-like effects of high-dose ketamine in mice.

Authors:  Jianjun Yang; Zhiqiang Zhou; Chun Yang
Journal:  Psychopharmacology (Berl)       Date:  2011-04-19       Impact factor: 4.530

Review 3.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

4.  Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice.

Authors:  Rachel J Donahue; John W Muschamp; Scott J Russo; Eric J Nestler; William A Carlezon
Journal:  Biol Psychiatry       Date:  2014-01-08       Impact factor: 13.382

Review 5.  Rodent ketamine depression-related research: Finding patterns in a literature of variability.

Authors:  Andrew J Polis; Paul J Fitzgerald; Pho J Hale; Brendon O Watson
Journal:  Behav Brain Res       Date:  2019-08-13       Impact factor: 3.332

6.  Integrative analysis of sex differences in the rapid antidepressant effects of ketamine in preclinical models for individualized clinical outcomes.

Authors:  Samantha K Saland; Florian Duclot; Mohamed Kabbaj
Journal:  Curr Opin Behav Sci       Date:  2016-11-26

Review 7.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

8.  Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.

Authors:  Valentina Gigliucci; Grainne O'Dowd; Sheena Casey; Danielle Egan; Sinead Gibney; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

9.  Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice.

Authors:  Marika V Doucet; Hester Levine; Kumlesh K Dev; Andrew Harkin
Journal:  Neuropsychopharmacology       Date:  2013-02-27       Impact factor: 7.853

10.  Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.

Authors:  Zhen Ren; Horia Pribiag; Sarah J Jefferson; Matthew Shorey; Thomas Fuchs; David Stellwagen; Bernhard Luscher
Journal:  Biol Psychiatry       Date:  2016-02-13       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.